Market Cap | 9.52M | P/E | - | EPS this Y | 80.30% | Ern Qtrly Grth | - |
Income | -9.84M | Forward P/E | - | EPS next Y | - | 50D Avg Chg | -8.00% |
Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -28.00% |
Dividend | N/A | Price/Book | 0.87 | EPS next 5Y | - | 52W High Chg | -60.00% |
Recommedations | 2.00 | Quick Ratio | 0.82 | Shares Outstanding | 15.67M | 52W Low Chg | 15.00% |
Insider Own | 8.51% | ROA | -53.57% | Shares Float | 12.09M | Beta | 1.03 |
Inst Own | 16.80% | ROE | -111.99% | Shares Shorted/Prior | 352.65K/76.83K | Price | 0.82 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 977,687 | Target Price | - |
Oper. Margin | - | Earnings Date | - | Volume | 29,182 | Change | -0.39% |
Sharps Technology, Inc., a medical device company, researches, designs, develops, manufactures, distributes, and sells safety syringe products in the United States. It offers Sharps Provensa, an ultra-low waste space syringe for the administration of various vaccines and injectable medications. Sharps Technology, Inc. was incorporated in 2017 and is based in Melville, New York.
Aegis Capital | Buy | May 9, 23 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Hayes Robert Michael | Chief Executive Offi.. Chief Executive Officer | Jan 31 | Buy | 0.37 | 10,200 | 3,774 | 75,882 | 02/05/24 |
Ruemler Timothy James | Director Director | Jan 02 | Buy | 0.4 | 9,466 | 3,786 | 1,061,675 | 01/04/24 |
Crescenzo Andrew R. | Chief Financial Offi.. Chief Financial Officer | Dec 28 | Buy | 0.4216 | 3,500 | 1,476 | 15,500 | 12/29/23 |
Ruemler Timothy James | Director Director | Dec 22 | Buy | 0.4016 | 10,000 | 4,016 | 1,052,209 | 12/22/23 |
Ruemler Timothy James | Director Director | Nov 22 | Buy | 0.45 | 10,000 | 4,500 | 1,042,209 | 11/27/23 |
Ruemler Timothy James | Director Director | Nov 17 | Buy | 0.41 | 15,000 | 6,150 | 1,022,209 | 11/21/23 |
Ruemler Timothy James | Director Director | Nov 15 | Buy | 0.41 | 6,000 | 2,460 | 1,017,209 | 11/17/23 |
Hayes Robert Michael | Chief Executive Offi.. Chief Executive Officer | Apr 14 | Buy | 1.28 | 4,000 | 5,120 | 65,682 | 04/18/23 |
Hayes Robert Michael | Chief Executive Offi.. Chief Executive Officer | Mar 13 | Buy | 1.36 | 5,100 | 6,936 | 61,682 | 03/15/23 |
Hayes Robert Michael | Chief Executive Offi.. Chief Executive Officer | Feb 17 | Buy | 1.36 | 3,500 | 4,760 | 56,582 | 02/22/23 |
Hayes Robert Michael | Chief Executive Offi.. Chief Executive Officer | Sep 02 | Buy | 1.35 | 5,000 | 6,750 | 53,082 | 09/07/22 |
Hayes Robert Michael | Chief Executive Offi.. Chief Executive Officer | Aug 30 | Buy | 1.35 | 8,073 | 10,899 | 48,082 | 09/01/22 |
Hayes Robert Michael | Chief Executive Offi.. Chief Executive Officer | Aug 26 | Buy | 1.41 | 4,009 | 5,653 | 40,009 | 08/30/22 |
Hayes Robert Michael | Chief Executive Offi.. Chief Executive Officer | Aug 22 | Buy | 1.29 | 4,000 | 5,160 | 36,000 | 08/24/22 |
Hayes Robert Michael | Chief Executive Offi.. Chief Executive Officer | Aug 04 | Buy | 1.15 | 2,000 | 2,300 | 32,000 | 08/08/22 |
Hayes Robert Michael | Chief Executive Offi.. Chief Executive Officer | May 20 | Buy | 1.21 | 5,000 | 6,050 | 25,000 | 05/23/22 |
Hayes Robert Michael | Chief Executive Offi.. Chief Executive Officer | Apr 27 | Buy | 1.48 | 4,000 | 5,920 | 14,000 | 05/02/22 |
Blackman Alan R. | CIO and COO CIO and COO | Apr 22 | Buy | 1.52 | 5,000 | 7,600 | 728,429 | 04/25/22 |
Ruemler Timothy James | Director Director | Apr 14 | Buy | 4.25 | 29,400 | 124,950 | 890,406 | 04/18/22 |
Hayes Robert Michael | Chief Executive Offi.. Chief Executive Officer | Apr 14 | Buy | 2.06 | 7,000 | 14,420 | 7,000 | 04/18/22 |
Blackman Alan R. | CIO and COO CIO and COO | Apr 14 | Buy | 4.25 | 4,000 | 17,000 | 723,429 | 04/18/22 |